Immune Cell Therapy Articles & Analysis
24 news found
Microsphere formulation has been highlighted as a promising dosage form in clinical practice due to its ability to significantly improve patient convenience and compliance. As a trustworthy partner in the field of pharmaceutical formulation, CD Formulation has newly introduced a range of raw materials for the production of microspheres and microneedles, which are highly expected to advance ...
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced promising new in vivo combination data that support the potential of the company’s novel gaseous nitric oxide (gNO) therapy to treat various types of solid tumors in combination with immune ...
Melbourne, Australia, 09 January 2023 – Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has been granted Chinese patent ZL 201680069543.6, entitled “Genetically modified cells and uses thereof”. ...
This further expands the GlycoConnect™ ADC tool kit by significantly enhancing the versatility across cytotoxic payloads and supports further expansion into antibody-based targeted gene therapy and immune cell engager ...
“This advisory board brings together invaluable expertise in hematological and solid cancers as well as the biology of NK cells and their application to further the development of our novel and highly potent innate immune cell-engaging ...
The International Society for Cell & Gene Therapy (ISCT) and The National Science Foundation (NSF) Engineering Research Center for Cell Manufacturing Technologies (CMaT) led by the Georgia Institute of Technology are pleased to launch the first joint-training program of our partnership, Workforce Development in Biomanufacturing – A ...
Dr. Elias Zerhouni, ModeX Chairman, former President of Global R&D at Sanofi and former NIH Director, named President and Vice Chairman of OPKO Dr. Gary Nabel, ModeX President and CEO, former Chief Scientific Officer at Sanofi and founder of NIH’s Vaccine Research Center, joins OPKO as Chief Innovation Officer and a member of OPKO’s Board of Directors Alexis Borisy, ModeX Lead ...
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), notes findings by a team of physician-scientists led by principal investigator Dr. Amir Jazaeri, professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, and reported at the annual meeting of Society of Gynecologic Oncology (SGO) in Phoenix, AZ, that a subset of patients with ovarian clear ...
MB097 is a fully defined LBT comprising a consortium of bacteria at the core of Microbiotica’s clinical microbiome signature predictive of patient response to Immune Checkpoint Inhibitor therapy. MB310 is a fully defined LBT comprising a consortium of bacteria for the treatment of Ulcerative Colitis (UC) identified as being linked to remission in a UC ...
(Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a collaboration with Rutgers, The State University of New Jersey. The collaboration will focus on the discovery and development of novel ...
Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the publication of a paper on personalized therapy with EVX-01 in patients with metastatic melanoma in the open access, peer-reviewed journal OncoImmunology. ...
Abecma is the first CAR T cell therapy approved for the treatment of R/R multiple myeloma in Japan. ...
Kovach M.D, commented that “recent advances in therapy with immune checkpoint inhibitors have been a true breakthrough in the development of more effective and less toxic treatment for many cancers. ...
CellworksGroup, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced the results from two clinical studies using the Cellworks Biosimulation Platform and Computational Omics Biology Model (CBM) to predict therapy response for individual MDS patients were featured in two poster presentations at the 63rd American Society of ...
Orally available Alphataxin, is the first and only drug in development to increase formation of CD4+ helper T cells. Immune checkpoint inhibitor therapy, the vanguard of cancer therapy, promotes the ability of CD8+ T cells to kill tumor cells. ...
Also, this conference was a highlight such as CD80-CD28 mechanism, NK cell therapy, bone marrow-derived immune cell and GI-101 is centered among the various immune checkpoint ...
s (Janssen's) targeted therapy. "The FDA's approval of Oncomine Dx Target Test enables clinicians to use FFPE tissue samples to identify patients in the U.S. who may benefit from this important new therapy," said Garret Hampton, president, clinical next-generation sequencing and oncology at Thermo Fisher Scientific. ...
This microbiome signature is a highly predictive clinical biomarker in advanced melanoma and is also predictive in non-small cell lung cancer (NSCLC). The bacteria most significantly linked to outcome are all elevated in patients that respond to anti-PD1 based therapy, suggesting that gut microbes drive ICI efficacy by enhancing the anti-tumour ...
Both the acquisition and new hires will advance the company’s work in single cell functional genomics with the goal of better supporting discovery, prioritization, and development of new therapies and drug combinations. Dropprint Genomics, a Y Combinator-backed startup, has developed computational infrastructure to conduct single-cell ...
ByImmunai
Since launching in 2018, the New York City-based company has focused its efforts on multiomic profiling of the immune system and building its Annotated Multiomic Immune Cell Atlas (AMICA). ...
ByImmunai